Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.33 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.32 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102863 | 0.97 | NCF1 (0.39) | NCF1CYP3A4CYP2C9CYP2C19PLG | |
| Hydrochloric Acid SCHEMBL16033739 | 0.92 | NCF1 (0.36) | NCF1CYP3A4CYP2C9CYP2C19PLG | |
| Hydrochloric Acid SCHEMBL30540602 | 0.85 | APLNR (0.37) | NCF1CYP3A4CYP2C9CYP2C19CHRM2 | |
| SCHEMBL19744251 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16323175 | 0.80 | MAOB (0.36) | CHRM2CHRM1CHRM3MAOB | |
| SCHEMBL4330357 | 0.80 | PLG (0.42) | PLGPLATLMNACHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL30281236 | 0.80 | PLG (0.42) | PLGPLATLMNACHRM2CHRM1 | |
| SCHEMBL21622137 | 0.77 | NCF1 (0.41) | NCF1CYP3A4CYP2C9CYP2C19PLG | |
| SCHEMBL19555539 | 0.77 | CHRM2 (0.37) | CHRM2CHRM1CHRM3MAOB | |
| Hydrochloric Acid SCHEMBL3589807 | 0.76 | NCF1 (0.39) | NCF1CYP3A4CYP2C9CYP2C19PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877382-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | VIVOZON, INC. (KR) | 2025-10-30 | — | — | US | disclosed |
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON, INC. (KR) | 2025-10-07 | — | — | US | disclosed |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
| CN-113260616-B | Novel compounds for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-113272298-B | Compounds and compositions for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | WESTVAC BIOPHARMA CO., LTD. (CN) | 2025-02-27 | — | — | US | disclosed |
| CN-116234552-B | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2025-02-25 | — | — | CN | disclosed |
| US-12215095-B2 | Compounds for the treatment of respiratory diseases | THE UNIVERSITY OF MELBOURNE (AU) | 2025-02-04 | — | — | US | disclosed |
| EP-4488264-A1 | KETO AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | WestVac Biopharma Co., Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| EP-1670790-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670769-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006033631-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF I | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033630-A1 | COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF III | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033628-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1636193-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030762-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030732-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2004108688-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | CHRM2 965/4885CHRM1 1108/4885CHRM3 752/4885 |
| US-12215095-B2 | Compounds for the treatment of respiratory diseases | LTB4R2, LTC4S, CCL11 | CHRM2 215/4885CHRM1 374/4885CHRM3 30/4885 |
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | CHRM2 3052/4885CHRM1 3567/4885CHRM3 2013/4885 |
| US-20250332138-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER | GRM5, HTR5A, HTR2A | CHRM2 1132/4885CHRM1 1290/4885CHRM3 656/4885 |
| US-20250064789-A1 | KETOAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ACE2, ACE, PKD2 | CHRM2 4573/4885CHRM1 4577/4885CHRM3 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.